On May 29, 2020 COTA, Inc., a healthcare technology company that uses real-world data (RWD) to bring clarity to cancer care, is pleased to announce its involvement and participation in two industry leading conferences – the 2020 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Virtual Scientific Program taking place May 29-31 and the DIA 2020 Virtual Global Annual Meeting to be held June 14-18 (Press release, COTA, MAY 29, 2020, View Source [SID1234558769]). Collectively, the involvement at these two premier events further underscores the importance of RWD’s role in clinical research and oncology care delivery.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"As real-world data continues to play an increasing role in clinical research with expanding regulatory applications, COTA is proud to be a leader in the space, and share our expertise and findings at two of the industry’s most important meetings," said Mike Doyle, President and CEO of COTA. "Not only are we working to provide clinically relevant insights that might otherwise remain hidden, but we are doing so by collaborating with industry experts, including Friends Of Cancer Research. This work is more important than ever during these unprecedented times, and we look forward to sharing our findings with conference attendees."
ASCO 2020 Areas of Study and Abstracts
The company is proud to announce that five abstracts have been accepted at ASCO (Free ASCO Whitepaper)’s 2020 annual meeting. The key areas of study include the following:
Characterization of African-American patients with multiple myeloma including time to 1st line therapy and 1st stem cell transplant.
Two abstracts as part of the Friends of Cancer Research RWE collaboration in oncology (Pilot 2.0)
Heterogeneity in the timing of IO uptake among patients with advanced non-small cell lung cancer
An analysis of patients with advanced non-small cell lung cancer to highlight the ability of RWD to generate evidence on patients that are routinely excluded from clinical trials.
Molecular markers of an NCCN-IPI prognostic model and its predictive power in a RWD cohort of patients with diffuse large b-cell lymphoma.
A literature review on techniques for the assessment of real-world progression and response to treatment in patients with multiple myeloma.
COTA has partnered with leading organizations, life science companies, hospitals, and cancer centers to produce these important findings. Links to the full abstracts and additional author information can be found below:
1. Incorporating molecular markers in standard prognostic models for DLBCL patients using real-world data.
2. Disparities in clinical characteristics and treatment of multiple myeloma in African American patients.
3. Trends in immunotherapy use in patients with advanced non-small cell lung cancer (aNSCLC) patients: Analysis of real-world data.
4. Overall survival (OS) in advanced non-small cell lung cancer (aNSCLC) patients treated with frontline chemotherapy or immunotherapy by comorbidity: A real-world data (RWD) collaboration.
5. Assessing real-world clinical response in patients with multiple myeloma (MM): A survey of the literature.
Industry Thought Leaders to Share Expertise at DIA 2020
In addition to its involvement in ASCO (Free ASCO Whitepaper)20, the Company will also be participating in DIA 2020, leading panel discussions with industry experts and thought leaders.
#301 SL: Combining Multiple Real World Data Sources to Maximize Value, will be held Wednesday, June 17, 2020 at 8:00 am. The discussion, led by COTA’s Chief Medical Officer, C.K. Wang, M.D., will discuss the approach and complexities to working with different real world datasets.
Panelists include Kim Van Naarden Braun, Associate Director, Translational Epidemiology, Informatics and Predictive Science, Bristol-Myers Squibb Company; Jennifer Christian, Vice President, Clinical Evidence and Epidemiology, IQVIA; and Jeremy Rassen, President and Chief Science Officer, Aetion.
#509 OD: ON DEMAND – Faster, Better, Cheaper: The Changing Role of Real World Data in Drug Development, will be available on demand for conference attendees. The session will explore how clinical trials will evolve in the era of big data from key regulatory leaders and real-world data experts. The discussion will be moderated by COTA’s Vice President of Life Sciences, Viraj Narayanan, MBA.
Panelists include Sean Khozin, Global Head of Data Strategy, Janssen Research & Development, LLC; Kimberly Wilson, Senior Director, Translational Epidemiology, Bristol-Myers Squibb Company; and Christopher Boone, Vice President, Global Head, Health Economics and Outcomes Research, Abbvie.
"As the value of real-world data becomes more accepted and its use more widely adopted, we are looking forward to speaking with industry leaders with invaluable insights on the topic," said CK Wang, M.D., COTA’s Chief Medical Officer. "With expertise spanning from a past Associate Director of the FDA, to an epidemiologist with over 20 years of healthcare research experience, as well as a pharmacoepidemiologist with 25 years of academic and industry experience, these will be fruitful discussions that can help push the industry forward as it expands its use of RWD."